Key Facts Surrounding This News Item
- CLBS had a POWR Rating of B (Buy) coming into today.
- CLBS was 18.68% above its 10-Day Moving Average coming into today.
- CLBS was 30.91% above its 20-Day Moving Average coming into today.
- CLBS was 38.78% above its 50-Day Moving Average coming into today.
- CLBS was 54.29% above its 100-Day Moving Average coming into today.
- CLBS was 45.35% above its 200-Day Moving Average coming into today.
- CLBS had returned +63.25% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.
More Info About Caladrius Biosciences, Inc. (CLBS)
Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. View our full CLBS ticker page with ratings, news, and more.
Try StockNews.com Premium Today!
Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!